<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505853</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AS1-004</org_study_id>
    <nct_id>NCT03505853</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)</brief_title>
  <official_title>A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of
      the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and
      their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail metabolites</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail metabolites</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Terminal half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktail</measure>
    <time_frame>Days 1 and 36</time_frame>
    <description>Volume of distribution (V/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic (PD) effect of givosiran on urine levels of delta-aminolevulinic acid (ALA)</measure>
    <time_frame>Days 1, 8, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic (PD) effect of givosiran on urine levels of Porphobilinogen (PBG) in patients with AIP</measure>
    <time_frame>Days 1, 8, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as evaluated by the proportion of subjects experiencing adverse events (AEs)</measure>
    <time_frame>Day 1 - Day 92</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Intermittent Porphyria (AIP)</condition>
  <condition>Acute Hepatic Porphyria (AHP)</condition>
  <condition>Porphyria, Acute Intermittent</condition>
  <condition>Acute Porphyria</condition>
  <arm_group>
    <arm_group_label>Givosiran with 5-probe cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Givosiran</intervention_name>
    <description>single dose of givosiran by subcutaneous (sc) injection</description>
    <arm_group_label>Givosiran with 5-probe cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-probe cocktail</intervention_name>
    <description>includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan</description>
    <arm_group_label>Givosiran with 5-probe cocktail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years old

          -  Weight between 45kg and 110kg, inclusive, if male

          -  Weight between 45kg and 100 kg, inclusive, if female

          -  Diagnosis of acute intermittent porphyria (AIP)

          -  Elevated urine PBG level

          -  Not be pregnant or breast feeding, and must be willing to use a highly effective
             method of contraception

        Exclusion Criteria:

          -  Clinically significant abnormal laboratory results

          -  Experienced an acute porphyria attack within past 12 months

          -  History of multiple drug allergies, intolerances or sensitivities

          -  History of recurrent pancreatitis

          -  Received an experimental drug, within 3 months of dosing

          -  Donated or lost an excessive amount of blood within 60 days of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Najafian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trials Information Line</last_name>
    <phone>617-575-7400</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trials Information Line</last_name>
    <phone>1-866-330-0326</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Porphyria</keyword>
  <keyword>Acute Hepatic Porphyria (AHP)</keyword>
  <keyword>Acute Intermittent Porphyria (AIP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyria, Acute Intermittent</mesh_term>
    <mesh_term>Coproporphyria, Hereditary</mesh_term>
    <mesh_term>Porphyrias, Hepatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

